Crohn Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Importantly, TNF-alpha, IFN-gamma, CD40L, and IL-23 transcripts increased in active CD only.
|
14605835 |
2004 |
Crohn Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Elevation of IL-23p19 transcript levels in CD correlated with the severity of endoscopic lesions.
|
15674109 |
2005 |
Crohn Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Notably, the recently described IL-23 shares the p40 subunit with IL-12, raising the possibility that the clinical benefit of the anti-IL-12/p40 antibody in CD may also be due to the neutralization of IL-23 activity.
|
17007011 |
2006 |
Crohn Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Collectively, these data suggest that this IL-23/IFN-gamma-positive feedback loop induced by abnormal intestinal macrophages contributes to the pathogenesis of chronic intestinal inflammation in patients with CD.
|
18497880 |
2008 |
Crohn Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our findings suggest that activation of the IL-23/IL-17 axis is fundamentally connected to the etiology of CD and may represent the basis for the relapsing nature of the disease by increasing the sensitivity of epithelium to microbial LPS.
|
18512248 |
2008 |
Crohn Disease
|
0.100 |
AlteredExpression
|
disease |
LHGDN |
Collectively, these data suggest that this IL-23/IFN-gamma-positive feedback loop induced by abnormal intestinal macrophages contributes to the pathogenesis of chronic intestinal inflammation in patients with CD.
|
18497880 |
2008 |
Crohn Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We demonstrated a strong and significant up-regulation of IL-23p19 transcripts in the terminal ileum in patients with AS and patients with CD.
|
19333939 |
2009 |
Crohn Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Genome-wide association studies have linked CD to a number of IL-23 pathway genes, notably IL23R (interleukin 23 receptor).
|
18976050 |
2009 |
Crohn Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Of CD susceptibility genes identified by genome-wide association scan IL-23A, JAK2, and STAT3 were upregulated in the CD group, confirming the dysregulation of Th17 signaling.
|
20848455 |
2010 |
Crohn Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The levels of IL-17A and IL-23 mRNA were significantly higher in UC than in CD while the levels of IL-6 were significantly higher in CD compared with UC.
|
21945121 |
2011 |
Crohn Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Indeed, genes important in the regulation of the IL-17-IL-23 pathway and, in Crohn's disease, genes important for autophagy (that is, NOD2 and ATG16L1 and IRGM) have a role in conferring susceptibility of individuals to these diseases.
|
22487796 |
2012 |
Crohn Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We quantified the transcriptional expression of IL-23, IL-12, IL-17A, IL-17F, IL-6, and IL-10 in healthy, noninflammatory duodenum, ileum, and colon and in inflamed and noninflamed biopsies of pediatric patients with Crohn's disease (CD) and ulcerative colitis (UC).
|
21994045 |
2012 |
Crohn Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Therefore, we suggest that loss of miR-29-mediated immunoregulation in CD DCs might contribute to elevated IL-23 in this disease.
|
24054330 |
2013 |
Crohn Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
The mRNA expression of interleukin-8 (IL-8), induced protein-10, tumour necrosis factor-alpha, IL-23 p19 and IL-12 p40, and Toll-like receptors (TLR) 1 and 2 in the ulcerated mucosa was increased in both intestinal TB and Crohn's disease.
|
23575333 |
2013 |
Crohn Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The different IL23A expression between UC and CD suggests an IBD subtype specific role.
|
23468882 |
2013 |
Crohn Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Given that an enhanced induction of innate-immunity associated cytokines IL-6 and IL-23, which promote IL-17 immunity, is also clearly implicated in CD, we hypothesized that monocyte-derived dendritic cells (moDCs) of CD patient origin would mount exaggerated IL-17A responses in T cells.
|
24635023 |
2014 |
Crohn Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Attenuated TNFα and IL-23 release from CD macrophages was found after infection with all E. coli strains.
|
25809337 |
2015 |
Crohn Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Furthermore, genetically determined high activity of the IL-23/IL-17 pathway was associated with increased risk of CD and UC.
|
26698117 |
2015 |
Crohn Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
IL-23 Blockade for Crohn s disease: next generation of anti-cytokine therapy.
|
28067059 |
2017 |
Crohn Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
The interleukin (IL)-12/IL-23 pathway has been a therapeutic target of interest in controlling active Crohn's disease (CD).
|
28838416 |
2017 |
Crohn Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Therefore, selective blockade of interleukin-23 via inhibition of p19 might be a viable therapeutic approach in Crohn's disease.
|
28411872 |
2017 |
Crohn Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Targeting the specific p19 subunit of IL23 is a promising strategy in CD.
|
30056776 |
2018 |
Crohn Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Ustekinumab is an interleukin inhibitor which blocks the p40 subunit of IL-12 and IL-23 axis and is already approved for the treatment of Crohn's disease patients, specially those who had inadequate response or intolerance to conventional treatment with anti-TNF-α agents.
|
29846261 |
2018 |
Crohn Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Lastly, ustekinumab, a monoclonal antibody (mAb) to the p40 subunit of IL-12 and IL-23, has showed good efficacy and safety profile in patients with Crohn's disease (CD).
|
30060945 |
2018 |
Crohn Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Areas covered: This review summarizes the available data on the role of IL-23 in CD and discusses the therapeutic relevance of blocking the function of IL-23 in this disorder.
|
30223688 |
2018 |